Study of simulect-based, steroid-free immunosuppressive regimen in HCV+ de novo liver transplant patients: preliminary results.
Filipponi
F
F
Simulect in HCV+ Liver Transplant Study Group, S.O. Trapiantologia Epatica Universitaria, Ospedale Cisanello, Pisa, Italy.
Salizzoni
M
M
Grazi
G
G
Pisati
R
R
Ferrara
R
R
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D004311:Double-Blind Method; D004351:Drug Resistance; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012008:Recurrence; D013256:Steroids / Q000037:antagonists & inhibitors; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D013256:Steroids; D000077552:Basiliximab